Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 260

1.

Respiratory tract immunization of non-human primates with a Newcastle disease virus-vectored vaccine candidate against Ebola virus elicits a neutralizing antibody response.

DiNapoli JM, Yang L, Samal SK, Murphy BR, Collins PL, Bukreyev A.

Vaccine. 2010 Dec 10;29(1):17-25. doi: 10.1016/j.vaccine.2010.10.024. Epub 2010 Oct 27.

2.

Attenuated Human Parainfluenza Virus Type 1 Expressing Ebola Virus Glycoprotein GP Administered Intranasally Is Immunogenic in African Green Monkeys.

Lingemann M, Liu X, Surman S, Liang B, Herbert R, Hackenberg AD, Buchholz UJ, Collins PL, Munir S.

J Virol. 2017 Apr 28;91(10). pii: e02469-16. doi: 10.1128/JVI.02469-16. Print 2017 May 15.

PMID:
28250127
3.

Mucosal parainfluenza virus-vectored vaccine against Ebola virus replicates in the respiratory tract of vector-immune monkeys and is immunogenic.

Bukreyev AA, Dinapoli JM, Yang L, Murphy BR, Collins PL.

Virology. 2010 Apr 10;399(2):290-8. doi: 10.1016/j.virol.2010.01.015. Epub 2010 Feb 2.

4.

Aerosolized Ebola vaccine protects primates and elicits lung-resident T cell responses.

Meyer M, Garron T, Lubaki NM, Mire CE, Fenton KA, Klages C, Olinger GG, Geisbert TW, Collins PL, Bukreyev A.

J Clin Invest. 2015 Aug 3;125(8):3241-55. doi: 10.1172/JCI81532. Epub 2015 Jul 13.

5.

A paramyxovirus-vectored intranasal vaccine against Ebola virus is immunogenic in vector-immune animals.

Yang L, Sanchez A, Ward JM, Murphy BR, Collins PL, Bukreyev A.

Virology. 2008 Aug 1;377(2):255-64. doi: 10.1016/j.virol.2008.04.029.

6.

A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethal-dose Ebola virus challenge.

Bukreyev A, Yang L, Zaki SR, Shieh WJ, Rollin PE, Murphy BR, Collins PL, Sanchez A.

J Virol. 2006 Mar;80(5):2267-79.

7.

Ebolavirus Glycoprotein Fc Fusion Protein Protects Guinea Pigs against Lethal Challenge.

Konduru K, Shurtleff AC, Bradfute SB, Nakamura S, Bavari S, Kaplan G.

PLoS One. 2016 Sep 13;11(9):e0162446. doi: 10.1371/journal.pone.0162446. eCollection 2016.

8.

Optimization of Prime-Boost Vaccination Strategies Against Mouse-Adapted Ebolavirus in a Short-Term Protection Study.

Aviles J, Bello A, Wong G, Fausther-Bovendo H, Qiu X, Kobinger G.

J Infect Dis. 2015 Oct 1;212 Suppl 2:S389-97. doi: 10.1093/infdis/jiv175. Epub 2015 Jun 2.

PMID:
26038398
9.

Successful topical respiratory tract immunization of primates against Ebola virus.

Bukreyev A, Rollin PE, Tate MK, Yang L, Zaki SR, Shieh WJ, Murphy BR, Collins PL, Sanchez A.

J Virol. 2007 Jun;81(12):6379-88. Epub 2007 Apr 11.

10.

Specific neutralizing response in plasma from convalescent patients of Ebola Virus Disease against the West Africa Makona variant of Ebola virus.

Luczkowiak J, Arribas JR, Gómez S, Jiménez-Yuste V, de la Calle F, Viejo A, Delgado R.

Virus Res. 2016 Feb 2;213:224-229. doi: 10.1016/j.virusres.2015.12.019. Epub 2015 Dec 29.

PMID:
26739425
11.

Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study.

Heppner DG Jr, Kemp TL, Martin BK, Ramsey WJ, Nichols R, Dasen EJ, Link CJ, Das R, Xu ZJ, Sheldon EA, Nowak TA, Monath TP; V920-004 study team.

Lancet Infect Dis. 2017 Aug;17(8):854-866. doi: 10.1016/S1473-3099(17)30313-4. Epub 2017 Jun 9.

PMID:
28606591
12.

Recombinant newcastle disease virus expressing a foreign viral antigen is attenuated and highly immunogenic in primates.

Bukreyev A, Huang Z, Yang L, Elankumaran S, St Claire M, Murphy BR, Samal SK, Collins PL.

J Virol. 2005 Nov;79(21):13275-84.

13.

Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice.

Bengtsson KL, Song H, Stertman L, Liu Y, Flyer DC, Massare MJ, Xu RH, Zhou B, Lu H, Kwilas SA, Hahn TJ, Kpamegan E, Hooper J, Carrion R Jr, Glenn G, Smith G.

Vaccine. 2016 Apr 7;34(16):1927-35. doi: 10.1016/j.vaccine.2016.02.033. Epub 2016 Feb 24.

14.

Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector.

Liang B, Ngwuta JO, Herbert R, Swerczek J, Dorward DW, Amaro-Carambot E, Mackow N, Kabatova B, Lingemann M, Surman S, Yang L, Chen M, Moin SM, Kumar A, McLellan JS, Kwong PD, Graham BS, Schaap-Nutt A, Collins PL, Munir S.

J Virol. 2016 Oct 14;90(21):10022-10038. Print 2016 Nov 1.

15.

Antibody quality and protection from lethal Ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccine.

Blaney JE, Marzi A, Willet M, Papaneri AB, Wirblich C, Feldmann F, Holbrook M, Jahrling P, Feldmann H, Schnell MJ.

PLoS Pathog. 2013;9(5):e1003389. doi: 10.1371/journal.ppat.1003389. Epub 2013 May 30.

16.

Human Polyclonal Antibodies Produced through DNA Vaccination of Transchromosomal Cattle Provide Mice with Post-Exposure Protection against Lethal Zaire and Sudan Ebolaviruses.

Bounds CE, Kwilas SA, Kuehne AI, Brannan JM, Bakken RR, Dye JM, Hooper JW, Dupuy LC, Ellefsen B, Hannaman D, Wu H, Jiao JA, Sullivan EJ, Schmaljohn CS.

PLoS One. 2015 Sep 30;10(9):e0137786. doi: 10.1371/journal.pone.0137786. eCollection 2015.

17.

Recombinant Modified Vaccinia Virus Ankara Generating Ebola Virus-Like Particles.

Schweneker M, Laimbacher AS, Zimmer G, Wagner S, Schraner EM, Wolferstätter M, Klingenberg M, Dirmeier U, Steigerwald R, Lauterbach H, Hochrein H, Chaplin P, Suter M, Hausmann J.

J Virol. 2017 May 12;91(11). pii: e00343-17. doi: 10.1128/JVI.00343-17. Print 2017 Jun 1.

PMID:
28331098
18.

Adenovirus-Vectored Vaccine Provides Postexposure Protection to Ebola Virus-Infected Nonhuman Primates.

Wong G, Richardson JS, Pillet S, Racine T, Patel A, Soule G, Ennis J, Turner J, Qiu X, Kobinger GP.

J Infect Dis. 2015 Oct 1;212 Suppl 2:S379-83. doi: 10.1093/infdis/jiv102. Epub 2015 May 9.

19.

Vesicular stomatitis virus-based vaccines protect nonhuman primates against Bundibugyo ebolavirus.

Mire CE, Geisbert JB, Marzi A, Agans KN, Feldmann H, Geisbert TW.

PLoS Negl Trop Dis. 2013 Dec 19;7(12):e2600. doi: 10.1371/journal.pntd.0002600. eCollection 2013.

20.

Newcastle disease virus-vectored vaccines expressing the hemagglutinin or neuraminidase protein of H5N1 highly pathogenic avian influenza virus protect against virus challenge in monkeys.

DiNapoli JM, Nayak B, Yang L, Finneyfrock BW, Cook A, Andersen H, Torres-Velez F, Murphy BR, Samal SK, Collins PL, Bukreyev A.

J Virol. 2010 Feb;84(3):1489-503. doi: 10.1128/JVI.01946-09. Epub 2009 Nov 18.

Supplemental Content

Support Center